ESMO 23: Pluvicto Fulfils Promise For Prostate Cancer Label Expansion
Executive Summary
Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.
You may also be interested in...
PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
Novartis Positive Post-Sandoz But Some Cancer Drugs Look Lackluster
Sans Sandoz, Novartis posts a beat-and-raise but its oncology franchise remains undistinguished.